Initial Evaluation and Management of Suspected Neonatal Inborn Error of Metabolism
When a neonate presents with suspected inborn error of metabolism, immediately obtain baseline investigations including glucose, arterial blood gas, lactate, ammonia, and ketones (GALAK), followed by specialized metabolic testing with plasma amino acids, urine organic acids, plasma carnitine, and acylcarnitine profile before initiating treatment. 1, 2
Clinical Recognition and Initial Assessment
High-Risk Clinical Presentations
Suspect IEM in any neonate presenting with:
- Acute illness mimicking sepsis with poor response to standard therapy 3
- Altered mental status, vomiting, or lethargy 4
- Overwhelming metabolic decompensation in the first days to weeks of life 2
- Nonspecific signs including poor feeding, hypotonia, seizures, or encephalopathy 1
Critical pitfall: IEM presentations are nonspecific and easily mistaken for common neonatal conditions like sepsis, requiring a high index of suspicion for timely diagnosis. 1, 3
Immediate Laboratory Evaluation (GALAK Panel)
Obtain these baseline investigations before starting treatment: 1
- Glucose: Identifies nonketotic hypoglycemia (suggests fatty acid oxidation defects) 2
- Arterial blood gas: Detects metabolic acidosis with elevated anion gap 2
- Lactate: Elevated in energy metabolism defects 1
- Ammonia: Critical for identifying hyperammonemia (urea cycle defects, organic acidemias) 2, 3
- Ketones: Absence with hypoglycemia suggests fatty acid oxidation disorders 2
Specialized Metabolic Testing
Confirmatory Diagnostic Studies
Once initial screening suggests IEM, obtain: 2
- Plasma amino acids: Identifies aminoacidopathies and urea cycle defects 5, 2
- Urine organic acids: Detects organic acidemias 5, 2
- Plasma carnitine (total and free): Evaluates carnitine deficiency and transport disorders 5, 2
- Acylcarnitine profile: Identifies fatty acid oxidation defects and organic acidemias 5
Additional Testing Based on Initial Results
Consider ordering: 5
- Liver function tests (may be abnormal in acute crisis)
- Creatine phosphokinase (CPK) (elevated in some fatty acid oxidation defects)
- Blood glucose monitoring (depends on feeding status)
Important caveat: Normal initial metabolic testing does not rule out IEM in many disorders, particularly fatty acid oxidation defects where abnormalities may only appear during metabolic stress. 5 Additional confirmatory testing with mutation analysis or enzyme assays is often required. 5
Classification-Based Diagnostic Approach
Group 1: Intoxication Disorders
Present with accumulation of toxic metabolites: 1
- Aminoacidopathies (phenylketonuria, maple syrup urine disease)
- Organic acidemias (propionic acidemia, methylmalonic acidemia)
- Urea cycle defects
Group 2: Energy Defects
Present with hypoglycemia, lactic acidosis, or hepatic dysfunction: 1
- Fatty acid oxidation disorders
- Mitochondrial disorders
- Glycogen storage diseases
Group 3: Storage Disorders
Present with progressive organomegaly, developmental regression, dysmorphic features: 2
- Lysosomal disorders
- Peroxisomal disorders
Immediate Management Principles
Four Pillars of Acute Treatment
Initiate therapy rapidly to prevent neurologic damage: 1, 6
- Substrate reduction: Stop protein/fat intake depending on suspected disorder 1, 6
- Provision of deficient metabolites: Provide glucose, specific cofactors, or missing compounds 1, 6
- Disposal of toxic metabolites: Use scavenger medications, dialysis for severe hyperammonemia 1, 6
- Increase enzyme activity: Administer cofactors (pyridoxine, biotin, carnitine) as indicated 1, 6
Life Support and Stabilization
- Immediate cardiorespiratory support and hydroelectrolyte balance 6
- Promote anabolism with high-calorie glucose infusions (10% dextrose at 1.5× maintenance) to prevent catabolism 6, 3
- Avoid fasting states that trigger metabolic decompensation 3
Newborn Screening Integration
Positive Screening Follow-Up
For infants with abnormal newborn screening results: 5
- Refer immediately to metabolic specialty center for formal evaluation 5
- Repeat acylcarnitine profile or specific metabolites as indicated 5
- Initiate mutation analysis when metabolites alone are insufficient for diagnosis (e.g., VLCAD, SCAD deficiency) 5
Key consideration: Positive predictive value of newborn screening can be as low as 10%, but actionable results require prompt evaluation to distinguish true disease from false positives. 5 Correct diagnostic confirmation is essential for appropriate management and reducing parental anxiety. 5
Diagnostic Confirmation Requirements
Most expanded newborn screening disorders require additional confirmatory steps beyond metabolite analysis: 5
- Persistence of abnormal metabolites on repeat testing
- Enzyme activity assays
- Mutation analysis identifying two pathological mutations in trans
- Even phenylketonuria requires ruling out biopterin synthesis defects 5
Prognostic Considerations
Critical outcome factor: Prompt identification and treatment initiation are crucial for neurological prognosis and prevention of death. 6 Despite optimal acute management, some patients experience developmental delay and chronic neurological dysfunction, emphasizing the importance of earliest possible intervention. 7
The goal is reducing morbidity and mortality through early recognition and timely treatment, as delayed diagnosis leads to irreversible neurologic damage in many IEM. 5, 6